Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1
Autore:
Germano, D; Pacilio, C; Cancemi, M; Cicatiello, L; Altucci, L; Petrizzi, VB; Sperandio, C; Salzano, S; Michalides, RJAM; Taya, Y; Bresciani, F; Weisz, A;
Indirizzi:
Univ Naples 2, Fac Med & Chirurg, Ist Patol Gen & Oncol, I-80138 Naples, Italy Univ Naples 2 Naples Italy I-80138 ol Gen & Oncol, I-80138 Naples, Italy Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulore & Mol L Calif, Naples, Italy Univ Naples Federico II Naples Italy ulore & Mol L Calif, Naples, Italy Netherlands Canc Inst, Dept Tumor Biol, Amsterdam, Netherlands NetherlandsCanc Inst Amsterdam Netherlands iol, Amsterdam, Netherlands Natl Canc Ctr, Res Inst, Div Biol, Tokyo 104, Japan Natl Canc Ctr Tokyo Japan 104 Ctr, Res Inst, Div Biol, Tokyo 104, Japan
Titolo Testata:
BREAST CANCER RESEARCH AND TREATMENT
fascicolo: 1, volume: 67, anno: 2001,
pagine: 23 - 33
SICI:
0167-6806(200105)67:1<23:IOHBCC>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
MAMMARY EPITHELIAL-CELLS; RAS TRANSGENIC MICE; DEPENDENT KINASE; FARNESYLTRANSFERASE INHIBITORS; TRANSFERASE INHIBITOR; E-CDK2 ACTIVATION; INDUCE APOPTOSIS; EXPRESSION; LOVASTATIN; TUMOR;
Keywords:
breast cancer; cell cycle; cyclin D1; estrogen; HMG-CoA reductase; protein prenylation; retinoblastoma protein; Simvastatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Weisz, A Univ Naples 2, Fac Med & Chirurg, Ist Patol Gen & Oncol, Larghetto S Aniello & Caponapoli 2, I-80138 Naples, Italy Univ Naples 2 Larghetto SAniello & Caponapoli 2 Naples Italy I-80138
Citazione:
D. Germano et al., "Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1", BREAST CANC, 67(1), 2001, pp. 23-33

Abstract

Overexpression of the cyclin D1 (CCND1) gene, encoding a downstream effector of mitogenic signals that plays a central role in G(1) phase progression, is often found in cancerous cells. In sporadic breast cancer (BC), this is one of the most frequent and early genetic lesions identified so far, found in more than 50% of the tumors. Inhibitors of the mevalonate/protein prenylation pathway belong to a new family of cancer therapeutic agents that act by blocking intracellular mitogenic signal transduction pathways, thereby preventing expansion of pre-cancerous foci and inhibiting growth of transformed cells. It is not known at present whether constitutively high intracellular levels of cyclin D1 might interfere with the cytostatic actions of mevalonate/protein prenylation inhibitors. This possibility was investigated here by assessing the cell cycle effects of Simvastatin, a non-toxic upstream inhibitor of the mevalonate pathway, on human BC MCF-7 cells expressing either normal or enhanced levels of cyclin D1 from of a stably transfected, tet-inducible expression vector. Results show that constitutive overexpression of this protein, such as that found in sporadic BCs, does not influence the growth inhibitory effects of Simvastatin in vitro. In addition, D1-overexpressing embryo fibroblasts were also found to be responsive to the cell cycle effects of mevalonate/protein prenylation pathway blockade, further suggesting that high intracellular levels of cyclin D1 do not prevent the cytostatic actions of compounds targeting this metabolic pathway.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 11:01:45